| Autor: |
Corbett JW; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA. jeffrey.w.corbett@pfizer.com, Rauckhorst MR, Qian F, Hoffman RL, Knauer CS, Fitzgerald LW |
| Jazyk: |
angličtina |
| Zdroj: |
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2007 Nov 15; Vol. 17 (22), pp. 6250-6. Date of Electronic Publication: 2007 Sep 07. |
| DOI: |
10.1016/j.bmcl.2007.09.008 |
| Abstrakt: |
Low nanomolar corticotropin releasing factor type-1 (CRF(1)) receptor antagonists containing unique indanylamines were identified from the heteroatom-linked pyrazine chemotype. The most potent indanylpyrazine had a K(i)=11+/-1 nM. The oxygen-linked pyrazinyl derivatives were prepared through a copper-catalyzed coupling of a pyridinone to a bromo- or iodopyrazine. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect